Treatment of chronic cough
Treatment of chronic cough
Patients with refractory chronic cough (RCC) often experience a lengthy investigation process with repeated medical visits without a fixed diagnosis.1,2 Current ERS guidelines recommend testing different symptom-relieving treatments in an attempt to clarify an underlying disease (e.g. treatment with inhaled steroids if asthma is suspected or PPIs if reflux disease is suspected).3
Suboptimal treatment is common
The ERS trial recommends low-dose morphine or codeine (if necessary), which have a general depressant effect on the central nervous system and can be sedating.3 Long-term use of morphine medications can be addictive.
Patients may feel that their disease is not being adequately addressed. This can leave them feeling frustrated as they are referred from doctor to doctor without getting rid of their chronic cough, which is associated with significant physical, social and psychological consequences.1,4,5
One survey reported that:
Of 1120 respondents, the majority of patients feel that their doctor does not manage their condition thoroughly enough.1
The medical treatment is ineffective.
72% of participants had been to the doctor ≥ 3 times.1
Only 53% had received a diagnosis.1
▼ LYFNUA® meets an unmet medical need
LYFNUA® (gefapixant) is a «first-in-class» treatment option for these patients.6,7
With LYFNUA®, patients with refractory chronic cough (RCC) get a clinically documented treatment option which, through a targeted effect on the peripheral sensory nervous system, reduces overactivity in the cough reflex.6
INDICATION
LYFNUA® is indicated in adults for the treatment of refractory or unexplained chronic cough (RCC).6
References:
- Chamberlain SA, Garrod R, Douiri A et al., The impact of chronic cough: a cross-sectional European survey. Lung. 2015 Jun;193(3):401-8.
- Koskela HO, Lätti AM, Pekkanen J. Risk factors for repetitive doctor’s consultations due to cough: a cross-sectional study in a Finnish employed population. BMJ Open. 2019 Jun 11;9(6):e030945.
- Morice AH, Millqvist E, Bieksiene K et al., ERS guidelines on the diagnosis and treatment of chronic cough in adults and children. Eur Respir J. 2020 Jan 2;55(1):1901136.
- Satia I, Badri H, Al-Sheklly B, Smith JA et al., Towards understanding and managing chronic cough. Clin Med (Lond). 2016 Dec;16(Suppl 6):s92-s97.
- Kuzniar TJ, Morgenthaler TI, Afessa B et al., Chronic cough from the patient’s perspective. Mayo Clin Proc. 2007 Jan;82(1):56-60.
- LYFNUA®, Summary of product characteristics, 09/2023, section 4.1 and 5.1
- Muccino D, Green S. Update on the clinical development of gefapixant, a P2X3 receptor antagonist for the treatment of refractory chronic cough. Pulm Pharmacol Ther. 2019 Jun;56:75-78.
▼ LYFNUA® (gefapiksant) 45 mg filmdrasjerte tabletter
Terapeutisk indikasjon: Lyfnua er indisert til voksne til behandling av refraktær eller uforklarlig kronisk hoste.
Dosering og administrasjonsmetode: Anbefalt dose av Lyfnua er én 45 mg tablett tatt oralt to ganger daglig med eller uten mat. Pasienter med alvorlig nyresvikt (eGFR < 30 mL/minutt/1,73 m²) som ikke krever dialyse, bør få en redusert dose på én 45 mg tablett som tas én gang daglig.
Pakker og priser (MRP): 56 filmdrasjerte tabletter (blisterpakke), 45 mg: kr 1445,90. Reseptgruppe: C.
Utvalgt sikkerhetsinformasjon:
Spesielle advarsler og forholdsregler for bruk: For pasienter med OSA (obstruktiv søvnapné), bør passende behandling for OSA vurderes før behandling med Lyfnua igangsettes. Lyfnua bør brukes med forsiktighet hos pasienter med kjent overfølsomhet for sulfonamider. Behandling med gefapiksant skal vurderes og tilpasses hos pasienter som utvikler en akutt infeksjon i nedre luftveier.
Fertilitets-, graviditets- og ammeinformasjon: Bruk av Lyfnua bør unngås under graviditet, hos kvinner med reproduksjonsmuligheter som ikke bruker prevensjon, og for ammende kvinner.
Bivirkninger: De vanligste bivirkningene med Lyfnua (som kan påvirke mer enn 1 av 10 personer) inkluderer smakforstyrrelser: dysgeusi (endringer i smakssansen, 41%), ageusi (tap av smakssans, 15%) og hypogeusi (redusert smakssans, 11%).
Konsulter LYFNUA SmPC 09/2023 før forskrivning eller bruk for fullstendig informasjon om dosering, kontraindikasjoner, advarsler og forholdsregler, interaksjoner og bivirkninger.
MSD (Norge) AS, Postboks 1S79 Vika, 0118 Oslo, tlf. 32 20 73 00 faks 32 20 73 10.
Copyright © 2025 Merck & Co., lnc., Rahway, NJ, USA og dets datterselskaper. Alle rettigheter forbeholdt.
NO-NON-00562
